SWOG clinical trial number
SWOG-8037

Combined Therapies for Squamous Cell Carcinoma of the Esophagus

Closed
Phase
Published
Abbreviated Title
Combined Therapies for Squamous Cell Carcinoma of the Esophagus
Activated
02/16/1981
Closed
01/19/1984

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

1987

Combined therapies for squamous-cell carcinoma of the esophagus, Southwest Oncology Group study.

E Poplin;T Fleming;L Leichman;HG Seydel;Z Steiger;S Taylor;R Vance;WJ Stuckey;SE Rivkin JCO 5(4):622-628

1986

SWOG 8037: Combined therapy for squamous cell carcinoma of theesophagus (SCCE).

E Poplin;L Leichman;G Seydel;Z Steiger;T Fleming ASCO 5:80(#311)

1984

Pre-operative adjuvant therapy for squamous cell cancer (SCC) of the esophagus: SWOG & RTOG clinical trials.

L Leichman;HG Seydel;Z Steiger ASCO #C-575

Combined preoperative chemotherapy and radiation therapy for cancer of the esophagus: The Wayne State University, Southwest Oncology Group and Radiation Therapy Oncology Group experience.

L Leichman;Z Steiger;HG Seydel;VK Vaitkevicius Semin Oncol 11(2):178-185

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase